好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Role of Brain Network Functional Connectivity and Machine Learning for the Classification and Characterization of Disease Phenotypes in Patients with Multiple Sclerosis
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
162

To develop advanced methods for the analysis of resting state (RS) functional connectivity (FC) to classify patients with multiple sclerosis (MS) according to disease phenotype.

RS FC graph theoretical analysis is helping to shed light into brain functional reorganization in MS. The application of advanced network-based methods exploiting machine learning on RS FC data may produce important clues to support MS patients’ classification.

RS fMRI scans were obtained from 46 healthy controls (HC) and 113 MS patients (62 relapsing-remitting [RR] and 51 progressive [P]MS). Dominant sets clustering was used to group covariance-based RS FC matrices into clusters of subjects sharing some similarities in their network configuration. Support vector machines (SVMs) were then used to classify disease phenotypes exploiting a representation of networks based on their geodesic distance from cluster means. Finally, a sensitivity analysis on the trained classifier was used to identify clusters and connections more relevant for classification.

The described machine learning tool was able to classify RRMS patients from HC with an accuracy of 72.5%, PMS patients from HC with an accuracy of 84.1% and PMS from RRMS patients with an accuracy of 76%. With the sensitivity analysis on trained SVMs we found that increased connectivity within the basal ganglia sub-network (particularly involving the bilateral thalami) and decreased RS FC within the temporal sub-network contributed to an accurate classification of both RRMS and PMS patients from HC. Moreover, decreased RS FC within the occipital and parietal sub-networks contributed to differentiate PMS patients from HC.

A combination of different machine learning principles allowed to detect specific RS FC configurations of our study subjects, which allowed to classify MS patients with different clinical phenotypes from HC with a good accuracy. Distinct sub-networks abnormalities contributed to an accurate classification of different phenotypes.

Authors/Disclosures
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)
PRESENTER
Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Paola Valsasina Paola Valsasina has nothing to disclose.
No disclosure on file
Paolo Preziosa (Ospedale San Raffaele) Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
No disclosure on file
No disclosure on file
No disclosure on file